Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Soleno Therapeutics, Inc. (SLNO) had Return on Tangible Equity of -73.79% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-175.85M |
|
-- |
|
-- |
|
$187.67M |
|
$-187.67M |
|
$11.82M |
|
$-175.85M |
|
$-175.85M |
|
$-175.85M |
|
$-175.85M |
|
$-175.85M |
|
$-175.85M |
|
$-187.67M |
|
$-185.68M |
|
40.18M |
|
40.18M |
|
$-4.38 |
|
$-4.38 |
|
| Balance Sheet Financials | |
$293.89M |
|
$0.19M |
|
$37.08M |
|
$330.97M |
|
$18.75M |
|
-- |
|
$67.11M |
|
$85.86M |
|
$245.11M |
|
$238.31M |
|
$245.11M |
|
45.70M |
|
| Cash Flow Statement Financials | |
$-69.10M |
|
$-225.68M |
|
$213.03M |
|
$169.68M |
|
$87.93M |
|
$-81.75M |
|
$99.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.68 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-69.31M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-71.74% |
|
|
Return on Tangible Equity |
-73.79% |
-53.13% |
|
-71.74% |
|
$5.36 |
|
$-1.73 |
|
$-1.72 |
|